Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464468 | 1.00 | MEN1 (0.49) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL12571280 | 1.00 | MEN1 (0.49) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL29398238 | 0.83 | GAA (0.58) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL29350888 | 0.83 | GAA (0.58) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL288272 | 0.83 | GAA (0.58) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL288260 | 0.83 | GAA (0.58) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL43168 | 0.83 | GAA (0.58) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL29350565 | 0.83 | GAA (0.58) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL14232832 | 0.82 | OPRM1 (0.48) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL12384380 | 0.82 | OPRM1 (0.48) | MEN1KMT2AOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842442-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | PREC PHARMACEUTICALS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3693375-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | Calithera Biosciences, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3368541-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10597411-B2 | Compositions and methods for inhibiting arginase activity | CALITHERA BIOSCIENCES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190330244-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | PRECISION PHARMACEUTICALS, INC. | 2019-10-31 | — | — | US | disclosed |
| WO-2018119440-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20170121352-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | PRECISION PHARMACEUTICALS, INC. | 2017-05-04 | — | — | US | disclosed |
| WO-2017075363-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-2897939-B1 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES FOR TREATING METABOLIC OR CARDIOVASCULAR DISEASES | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | disclosed |
| US-8003791-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7531526-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080132678-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2005053726-A1 | SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | MEN1 285/4885KMT2A 1853/4885OPRM1 2768/4885 |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | MEN1 2373/4885KMT2A 4259/4885OPRM1 4517/4885 |
| US-20170121352-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | ARG1, ARG2, PRMT5 | MEN1 3425/4885KMT2A 1704/4885OPRM1 3700/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MEN1 2997/4885KMT2A 2166/4885OPRM1 4336/4885 |
| US-20190330244-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | ARG1, ARG2, PRMT3 | MEN1 4058/4885KMT2A 2206/4885OPRM1 3381/4885 |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | MEN1 2373/4885KMT2A 4259/4885OPRM1 4517/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MEN1 2997/4885KMT2A 2166/4885OPRM1 4336/4885 |
| US-10597411-B2 | Compositions and methods for inhibiting arginase activity | ARG1, ARG2, PRMT3 | MEN1 4058/4885KMT2A 2206/4885OPRM1 3381/4885 |
| US-20080132678-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | MEN1 2373/4885KMT2A 4259/4885OPRM1 4517/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | MEN1 4760/4885KMT2A 1386/4885OPRM1 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.